Is Oric Pharmaceuticals, Inc. profitable?

Oric Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $135.2M over the trailing twelve months.

What is Oric Pharmaceuticals, Inc.'s earnings per share?

Oric Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.41.

Where does Oric Pharmaceuticals, Inc.'s income statement data come from?

Every line is extracted from Oric Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Oric Pharmaceuticals, Inc. ORIC Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$116.62M+6.2%	$109.82M-5.3%	$115.93M-2.1%	$118.36M+1.4%	$116.75M+2.3%
General and administrative	$33.29M+0.3%	$33.19M+3.4%	$32.09M+2.5%	$31.31M+4.8%	$29.87M+3.6%
Other operating expenses	$149.91M+4.8%	$143M-3.4%	$148.02M-1.1%	$149.67M+2.1%	$146.62M+2.6%
Total operating expenses	$149.91M+4.8%	$143M-3.4%	$148.02M-1.1%	$149.67M+2.1%	$146.62M+2.6%
Operating income	-$149.91M-4.8%	-$143M+3.4%	-$148.02M+1.1%	-$149.67M-2.1%	-$146.62M-2.6%
Other income (expense), net	$14.69M+8.5%	$13.54M+6.1%	$12.75M+2.7%	$12.42M-9.8%	$13.77M-8.5%
Net income	-$135.21M-4.4%	-$129.47M+4.3%	-$135.27M+1.4%	-$137.25M-3.3%	-$132.86M-3.9%
Diluted earnings per share	-$1.41+5.4%	-$1.49+13.9%	-$1.73+8.5%	-$1.89-1.1%	-$1.87-2.7%
Basic earnings per share	-$1.41+5.4%	-$1.49+13.9%	-$1.73+8.5%	-$1.89-1.1%	-$1.87-2.7%
Weighted-average shares, diluted	370.3M+10.3%	335.9M+5.7%	317.8M+9.8%	289.4M+2.8%	281.7M+1.3%
Weighted-average shares, basic	370.3M+10.3%	335.9M+5.7%	317.8M+9.8%	289.4M+2.8%	281.7M+1.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$135.71M-5.2%	-$129.06M+4.7%	-$135.38M+1.0%	-$136.81M-3.3%	-$132.49M-3.7%
Net unrealized gains (losses) on securities still held	-$499K-223%	$407K—	——	——	——
Research and development expense	$116.62M+6.2%	$109.82M-5.3%	$115.93M-2.1%	$118.36M+1.4%	$116.75M+2.3%
EBIT	-$149.91M-4.8%	-$143M+3.4%	-$148.02M+1.1%	-$149.67M-2.1%	-$146.62M-2.6%
EBITDA	-$148.72M-4.9%	-$141.78M+3.4%	-$146.82M+1.1%	-$148.48M-2.1%	-$145.48M-2.6%
EBITDA	-$148.72M-4.9%	-$141.78M+3.4%	-$146.82M+1.1%	-$148.48M-2.1%	-$145.48M-2.6%
EBIT	-$149.91M-4.8%	-$143M+3.4%	-$148.02M+1.1%	-$149.67M-2.1%	-$146.62M-2.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Oric Pharmaceuticals, Inc. profitable?: Oric Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $135.2M over the trailing twelve months.
What is Oric Pharmaceuticals, Inc.'s earnings per share?: Oric Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.41.
Where does Oric Pharmaceuticals, Inc.'s income statement data come from?: Every line is extracted from Oric Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.